SERPINB2 and non-small cell lung carcinoma: To further explore the potential of targeting the down-regulated SerpinB2 expression to overcome gefitinib resistance, we applied YD (Fig. 4a), an antitumor agent that effectively inhibits the proliferation of NSCLC cells and exhibits synergistic effect when combined with gefitinib27, 28, 31.